Browsing by Author Vicente, David

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中
Showing results 1 to 7 of 7
TitleAuthor(s)Issue Date
 
Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non–Small–Cell Lung Cancer (PACIFIC)
Journal:Clinical Lung Cancer
Socinski, Mark A.Özgüroğlu, MustafaVillegas, AugustoDaniel, DaveyVicente, DavidMurakami, ShujiHui, RinaGray, Jhanelle E.Park, KeunchilVincent, MarkMann, HelenNewton, MichaelDennis, Phillip A.Antonia, Scott J.
2021
 
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
Journal:Journal of Clinical Oncology
Spigel, David R.Faivre-Finn, CorinneGray, Jhanelle E.Vicente, DavidPlanchard, DavidPaz-Ares, LuisVansteenkiste, Johan F.Garassino, Marina C.Hui, RinaQuantin, XavierRimner, AndreasWu, Yi LongÖzgüroǧlu, MustafaLee, Ki H.Kato, TerufumiDe Wit, MaikeKurata, TakayasuReck, MartinCho, Byoung C.Senan, SureshNaidoo, JarushkaMann, HelenNewton, MichaelThiyagarajah, PirunthaAntonia, Scott J.
2022
 
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
Journal:Lung Cancer
Faivre-Finn, CorinneSpigel, David R.Senan, SureshLanger, CoreyPerez, Bradford A.Özgüroğlu, MustafaDaniel, DaveyVillegas, AugustoVicente, DavidHui, RinaMurakami, ShujiPaz-Ares, LuisBroadhurst, HelenWadsworth, CatherineDennis, Phillip A.Antonia, Scott J.
2021
 
Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC
Journal:New England Journal of Medicine
Antonia, Scott J.Villegas, AugustoDaniel, DaveyVicente, DavidMurakami, ShujiHui, RinaKurata, TakayasuChiappori, AlbertoLee, Ki H.De Wit, MaikeCho, Byoung C.Bourhaba, MaryamQuantin, XavierTokito, TakaakiMekhail, TarekPlanchard, DavidKim, Young ChulKarapetis, Christos S.Hiret, SandrineOstoros, GyulaKubota, KaoruGray, Jhanelle E.Paz-Ares, LuisDe Castro Carpeño, JavierFaivre-Finn, CorinneReck, MartinVansteenkiste, JohanSpigel, David R.Wadsworth, CatherineMelillo, GiovanniTaboada, MariaDennis, Phillip A.Özgüroğlu, Mustafa
2018
 
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study
Journal:The Lancet Oncology
Hui, RinaÖzgüroğlu, MustafaVillegas, AugustoDaniel, DaveyVicente, DavidMurakami, ShujiYokoi, TakashiChiappori, AlbertoLee, Ki Hyeongde Wit, MaikeCho, Byoung ChulGray, Jhanelle E.Rydén, AnnaViviers, LouisPoole, LynneZhang, YiduoDennis, Phillip A.Antonia, Scott J.
2019
 
Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer
Journal:Future Oncology
Garassino, Marina C.Paz-Ares, LuisHui, RinaFaivre-Finn, CorinneSpira, AlexPlanchard, DavidÖzgüroǧlu, MustafaDaniel, DaveyVicente, DavidMurakami, ShujiLanger, CoreySenan, SureshSpigel, DavidRydén, AnnaZhang, YiduoO'brien, CathyDennis, Phillip A.Antonia, Scott J.
2021
 
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC
Journal:Journal of Thoracic Oncology
Gray, Jhanelle E.Villegas, AugustoDaniel, DaveyVicente, DavidMurakami, ShujiHui, RinaKurata, TakayasuChiappori, AlbertoLee, Ki HyeongCho, Byoung ChulPlanchard, DavidPaz-Ares, LuisFaivre-Finn, CorinneVansteenkiste, Johan F.Spigel, David R.Wadsworth, CatherineTaboada, MariaDennis, Phillip A.Özgüroğlu, MustafaAntonia, Scott J.
2020
Showing results 1 to 7 of 7